ABEONA THERAPEUTICS INC. Annual Report - Your Investor's Guide

Welcome to your investor's guide for ABEONA THERAPEUTICS INC.'s annual report. This summary offers a clear look at the company's performance over the past year, highlighting key developments and what they mean for potential investors.

Business Overview (What They Do): ABEONA THERAPEUTICS INC. is a clinical-stage biopharmaceutical company that develops gene and cell therapies for rare and life-threatening diseases. Over the past year, the company significantly advanced its clinical pipeline. Like many development-stage biotech firms, it also faced financial challenges, primarily due to ongoing research and development efforts and strategic advancements in its drug candidates.

Financial Performance (The Numbers That Matter):

• Profitability: ABEONA recorded a net loss. This reflects substantial investment in research and development for its primary drug programs.

Management Discussion (Key Milestones & Hurdles):

• Major Wins: This year, ABEONA achieved significant advancements. It progressed its lead clinical programs, increased patient enrollment, generated more data for its gene therapy candidates, and maintained ongoing engagement with regulatory bodies.
• Challenges Faced: The company faced challenges including increased research and development expenses, the inherent risks of clinical development, and the continuous need for substantial future funding to support its pipeline.

Future Outlook & Competitive Position:

• Future Outlook (Strategic Direction): ABEONA's strategy focuses on advancing its lead gene therapy candidates through clinical development, seeking regulatory approvals, and exploring strategic partnerships to maximize its pipeline's value.
• Competitive Position (Competitive Landscape): In the rare genetic disease gene therapy sector, ABEONA competes with other biopharmaceutical companies developing similar gene therapies. It also competes with larger pharmaceutical companies that have broader research and development capabilities. ABEONA's competitive advantage stems from its proprietary gene therapy platform and its sharp focus on areas with high unmet medical needs.

Risk Factors:

• Key Risks: Investors should consider several key risks. These include potential clinical trial failures or delays for lead candidates, uncertainties and delays in regulatory approval, challenges in protecting intellectual property, reliance on third-party manufacturers, and the continuous need for significant additional capital to fund operations.
• Market & Regulatory Trends: The company navigates a dynamic environment shaped by the evolving regulatory landscape for gene therapies, advancements in gene editing technologies, and changes in healthcare policy affecting drug pricing or reimbursement.

Considering these points, investors should weigh the potential of ABEONA's pipeline against the inherent risks and financial needs of a clinical-stage biopharmaceutical company.